Group items tagged

Violent and abusive behaviour against pharmacists is impacting on recruitment and retention of staff in the sector, according to the Pharmacists' Defence Association (PDA). The trade union for pharmacists told BBC Breakfast TV on Wednesday (May 8) that its members have continuously raised workplace safety concerns due to an alarming rise in the incidents of abuse and violence against pharmacy staff. The PDA union has been calling for adequate risk assessments and preventative safety measures to be put in place in pharmacies whist adopting a zero-tolerance approach to violence and abuse. With several significant and worrying incidents involving PDA members, including a pharmacist being threatened with a knife recently, further research was conducted in April 2022 to establish the extent and impact of such behaviour on pharmacists. Forty-four per cent of the respondents in the survey reported that they or someone that they worked with had experienced physical or violent abuse in the last month.

The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."

The Pharmacists' Defence Association (PDA) has launched a brutal attack on some large pharmacy chains for full or part-day closures of some of their shops throughout the UK. It published an Open Letter on Tuesday (July 19) demanding urgent action "to protect patients by ensuring that essential community pharmacy services are provided safely and consistently". PDA chair Mark Koizol, who wrote the letter, went on to allege that many of those closure were "being orchestrated". He wrote that the "pharmacist shortage" narrative cited as a reason for these closures was "very different" from "the reality experienced by our members", including both employed and locum pharmacists. "We have evidence to show that these closures are being announced up to four weeks in advance," Koizol claimed. He gave examples of how a large company attempted to reduce the pre-agreed rate of locums and where this was not accepted, the shift was cancelled, resulting in the pharmacy being closed for part or full day.

While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasised that the patient safety and care must be the priority in hub and spoke dispensing. The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke dispensing but reaffirmed that patient care must be at the heart of future changes. With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly. In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported. RPS President Professor Claire Anderson said: "In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.

Pharmacists are being notified of a limited supply of hydrocortisone sodium phosphate 100mg/1ml solution for injection ampoules, with stock expected to be exhausted by late March 2025. The Department of Health and Social Care (DHSC) has issued a medicine supply notification, indicating that resupply is not anticipated until May 2026. NHS provider Trust pharmacy procurement and clinical teams are advised to collaborate in reserving existing stock of the solution for injection, specifically for patients who require hydrocortisone sodium phosphate during an adrenal crisis. The DHSC added that this stock has an expiry date of June 2025. Hydrocortisone is used to replace steroids in individuals with adrenal insufficiency, such as those with Congenital Adrenal Hyperplasia (CAH) or Addison's disease, where the adrenal glands produce insufficient natural steroids. People with adrenal insufficiency or anyone who is "steroid-dependent" require a hydrocortisone emergency injection kit to prevent an acute adrenal crisis, which can be life-threatening.

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness. Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680. Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's effectiveness or posed any risk to patient safety. The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion (400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.

The General Pharmaceutical Council (GPhC) today decided to convene a new group, involving all the key stakeholders, focused on assurance of practice post-registration. The decision in today's (9 December) council meeting follows the recommendation of a working group chaired by council member and pharmacist Aamer Safdar on the role of the regulator in post-registration education and training. The new group will be tasked with articulating a set of guiding principles where patient safety is the overarching priority, after carrying out a horizon scanning exercise to pull together an understanding of the system wide approach currently in place. The working group noted that the wider approach, in relation to regulation of post-registration practice and not simply education and training, may require the GPhC reviewing and developing its own control measures, and involving patients and the public in the next stages of work. Reviewing the work on online pharmacy services, the council meeting supported the regulator's plans to continue to require pharmacy websites to be arranged so that a person cannot choose a prescription only medicine and its quantity before there has been an appropriate consultation with a prescriber.

Teva UK has begun replacing its existing packaging with a new design which is "clearer and easier to read". The new look is "unique, recognisable and distinctive." It "enhances safety and provides a recognisable and distinguishable pack range." One of the UK's leading generics manufacturers, Teva UK supplies more than 500 generic pharmaceutical products to retail and hospital pharmacies. The company says each product within the portfolio is distinguishable by colour, ensuring no two different packs have the same drug and strength colours and with additional product information on the side of the pack and a simplified back, it makes it even easier to identify the correct product when dispensing and supports patients when taking their medication. "Our medicines impact the lives of millions of people every day and our packaging is often the first touchpoint for our patients and our customers", said Kim Innes, general manager of Teva UK and Ireland.